A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian Cancer

NCT05801783 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer
Peritoneal Carcinomatosis
Fallopian Tube Cancer

Interventions

DRUG: Recombinant oncolytic herpes simplex virus type 1 (R130)

Sponsor

Shanghai Yunying Medical Technology

Collaborators

[object Object]